Sihuan Pharmaceutical Holdings Group (HK:0460) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sihuan Pharmaceutical Holdings Group Ltd., a leader in the Chinese medical aesthetics market, has successfully renewed its exclusive distribution agreement with Hugel for the botulinum toxin product Letybo until 2030. Letybo has gained significant market share in China, with sales surging by over 50% year-on-year in the first half of 2024. The company is confident that its strategic partnership with Hugel will further establish Letybo as a top brand in China and add value for shareholders.
For further insights into HK:0460 stock, check out TipRanks’ Stock Analysis page.